Sepsis as a model of SIRS

被引:67
作者
Bhatia, Madhav [1 ]
He, Min [1 ]
Zhang, Huili [1 ]
Moochhala, Shabbir [2 ]
机构
[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Life Sci, Dept Pharmacol, Singapore 117456, Singapore
[2] DSO Natl Labs, Singapore 117510, Singapore
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2009年 / 14卷
基金
英国医学研究理事会;
关键词
Sepsis; Mouse; Rat; Substance P; Chemokines; Hydrogen sulfide; Review; SYSTEMIC INFLAMMATORY RESPONSE; HYDROGEN-SULFIDE; SEPTIC SHOCK; ENDOTOXIN-SHOCK; ANIMAL-MODELS; SUBSTANCE-P; PERITONEAL-LAVAGE; LABORATORY MODELS; CECAL LIGATION; LUNG INJURY;
D O I
10.2741/3561
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sepsis describes a complex clinical syndrome that results from the host inability to regulate the inflammatory response against infection. Despite more than 20 years of extensive study, sepsis and excessive systemic inflammatory response syndrome ( SIRS) are still the leading cause of death in intensive care units. The clinical study of sepsis and new therapeutics remains challenging due to the complexity of this disease. Therefore, many animal models have been employed to investigate the pathogenesis of sepsis and to preliminarily test potential therapeutics. However, so far, most therapeutics that have shown promising results in animal models failed in human clinical trials. In this chapter we will present an overview of different experimental animal models of sepsis and compare their advantages and disadvantage. The studies in animal models have greatly improved our understanding about the inflammatory mediators in sepsis. In this chapter we will also highlight the roles of several critical mediators including TNF-alpha, IL-1 beta, IL-6, chemokines, substance P, hydrogen sulfide and activated protein C in animal models of sepsis as well as in clinical studies.
引用
收藏
页码:4703 / 4711
页数:9
相关论文
共 61 条
[1]   Septic shock [J].
Astiz, ME ;
Rackow, EC .
LANCET, 1998, 351 (9114) :1501-1505
[2]  
BARTLETT JG, 1978, ARCH SURG-CHICAGO, V113, P853
[3]   Systemic neuropeptide levels as predictive indicators for lethal outcome in patients with postoperative sepsis [J].
Beer, S ;
Weighardt, H ;
Emmanuilidis, K ;
Harzenetter, MD ;
Matevossian, E ;
Heidecke, CD ;
Bartels, H ;
Siewert, JR ;
Holzmann, B .
CRITICAL CARE MEDICINE, 2002, 30 (08) :1794-1798
[4]   Sepsis and cytokines: Current status [J].
Blackwell, TS ;
Christman, JW .
BRITISH JOURNAL OF ANAESTHESIA, 1996, 77 (01) :110-117
[5]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[6]  
BORDEN EC, 1994, J LAB CLIN MED, V123, P824
[7]  
BROWNE MK, 1976, SURG GYNECOL OBSTET, V143, P738
[8]   Animal models of sepsis: Setting the stage [J].
Buras, JA ;
Holzmann, B ;
Sitkovsky, M .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (10) :854-865
[9]  
CARTER MS, 1990, J NEUROSCI, V10, P2203
[10]   Nitric oxide in shock [J].
Cauwels, A. .
KIDNEY INTERNATIONAL, 2007, 72 (05) :557-565